Steris (STE)
Health Care · Infection prevention and sterilization services
A global infection prevention leader providing sterilization equipment, consumables, and services to hospitals, surgical centers, and medical device manufacturers.
What Steris does
Steris is a leading global provider of products and services that support patient care with an emphasis on infection prevention. The company offers a comprehensive mix of consumable products (detergents, endoscopy accessories, barrier products, instruments), capital equipment (sterilizers, surgical tables, automated endoscope reprocessors), services (equipment installation, maintenance, instrument repair, laboratory testing, outsourced reprocessing), and connectivity solutions for operating rooms. Steris operates through three segments: Healthcare (serving sterile processing departments and procedural centers), Applied Sterilization Technologies (contract sterilization and laboratory testing for medical device and pharmaceutical manufacturers), and Life Sciences.
Themes: ["Infection prevention","Healthcare infrastructure","Aging population trends","Medical device sterilization","Hospital operations efficiency","Endoscopy and procedural care","Reusable medical instrument management","Contract sterilization services","Pharmaceutical manufacturing support"]
Fundamentals
- Price$216.00 as of 2026-07-09 close
- Market cap$20.9B as of 2026-07-10
- 1-year return-6.6% as of 2026-07-09 close
- P/E26.69 as of 2026-07-10
- Net margin+13.2% as of 2026-07-10
- Gross margin+44.3% as of 2026-07-10
- ROE+11.1% as of 2026-07-10
- Debt / equity0.27 as of 2026-07-10
- Revenue growth (YoY)+8.7% as of 2026-07-10
- Revenue CAGR (3y)+9.4% SEC XBRL
- Beta0.93 as of 2026-07-10
Dividend: yield +1.2%; 5-year non-decreasing per-share dividend streak (SEC XBRL).
Key risks (from latest filing)
["Significant competition from large diversified healthcare companies (3M, Baxter, Boston Scientific, Stryker, Olympus) and specialized regional competitors with varying product portfolios and geographic reach","Revenue concentration and growth dependency on healthcare industry dynamics, including government policies, aging population acceptance of healthcare technologies, and general economic conditions","Divestiture of Dental segment in fiscal 2025 creates transition risks; capital-intensive business model with substantial goodwill and intangible assets requiring ongoing acquisition integration"]
Competitors & peers
- 3M
- Baxter
- Boston Scientific
- Belimed
- Ecolab
- Fortive
- Getinge
- Olympus
- Stryker
Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-09.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.